Liver Cancer Immunity

HepatologyVolume 73, Issue S1 p. 86-103 Review Liver Cancer Immunity Sumera Rizvi, Corresponding Author Sumera Rizvi rizvi.sumera@mayo.edu Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN Address Correspondence and Reprint Requests to: Sumera Rizvi, M.B.B.S. Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science 200 First Street SW Rochester, MN 55905 E-mail: rizvi.sumera@mayo.edu Tel.: +507 538 4877Search for more papers by this authorJuan Wang, Juan Wang Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MNSearch for more papers by this authorAnthony B. El-Khoueiry, Anthony B. El-Khoueiry Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CASearch for more papers by this author Sumera Rizvi, Corresponding Author Sumera Rizvi rizvi.sumera@mayo.edu Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN Address Correspondence and Reprint Requests to: Sumera Rizvi, M.B.B.S. Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science 200 First Street SW Rochester, MN 55905 E-mail: rizvi.sumera@mayo.edu Tel.: +507 538 4877Search for more papers by this authorJuan Wang, Juan Wang Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MNSearch for more papers by this authorAnthony B. El-Khoueiry, Anthony B. El-Khoueiry Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CASearch for more papers by this author First published: 09 June 2020 https://doi.org/10.1002/hep.31416Citations: 10 Supported by the National Institute of Health (1K08CA236874-01[SR] and U01AA027681 [ABE]), Mayo Center for Cell Signaling in Gastroenterology (Pilot & Feasibility Award P30DK084567), American Gastroenterology Association Research Scholar Award, the Satter Family Liver Cancer Award, Hepatobiliary Cancer SPORE (P50 CA210964) Career Enhancement Program, and the Mayo Foundation. Potential conflict of interest: Dr. El-Khoueiry advises and received grants from AstraZeneca and Merck. He advises Bayer, Bristol Myers Squibb, EISAI, Exelixis, Agenus, Gilead, and Roche-Genentech. He received grants from Astex. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume73, IssueS1Special Issue: Cancers of the Liver ‐ Biology, Diagnosis and TreatmentJanuary 2021Pages 86-103 RelatedInformation